File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial

TitleSecond-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial
Authors
Issue Date2020
Citation
ESMO Open, 2020, v. 5, p. e000714 How to Cite?
Persistent Identifierhttp://hdl.handle.net/10722/289438

 

DC FieldValueLanguage
dc.contributor.authorKelley, RK-
dc.contributor.authorRyoo, BY-
dc.contributor.authorMerle, P-
dc.contributor.authorPark, JW-
dc.contributor.authorBolondi, L-
dc.contributor.authorChan, SL-
dc.contributor.authorLim, HY-
dc.contributor.authorBaron, AD-
dc.contributor.authorParnis, F-
dc.contributor.authorKnox, J-
dc.contributor.authorCattan, S-
dc.contributor.authorYau, TCC-
dc.contributor.authorLougheed, JC-
dc.contributor.authorMilwee, S-
dc.contributor.authorEl-Khoueiry, AB-
dc.contributor.authorCheng, AL-
dc.contributor.authorMeyer, T-
dc.contributor.authorAbou-Alfa, GK-
dc.date.accessioned2020-10-22T08:12:40Z-
dc.date.available2020-10-22T08:12:40Z-
dc.date.issued2020-
dc.identifier.citationESMO Open, 2020, v. 5, p. e000714-
dc.identifier.urihttp://hdl.handle.net/10722/289438-
dc.languageeng-
dc.relation.ispartofESMO Open-
dc.titleSecond-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial-
dc.typeArticle-
dc.identifier.emailYau, TCC: tyaucc@hku.hk-
dc.identifier.authorityYau, TCC=rp01466-
dc.identifier.doi10.1136/esmoopen-2020-000714-
dc.identifier.scopuseid_2-s2.0-85089984060-
dc.identifier.hkuros316114-
dc.identifier.volume5-
dc.identifier.spagee000714-
dc.identifier.epagee000714-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats